Moderna (Spikevax) Covid-19 vaccination 

11 August 2021

On 9 August 2021, the Therapeutic Goods Administration (TGA) gave provisional approval for the Moderna vaccine, whose brand name is Spikevax to be used within Australia.

This is the fourth vaccine to be given approval and the second mRNA vaccine approved.

The Moderna vaccine, like all provisionally approved vaccines, has undergone robust scientific evaluation to determine their safety, efficacy and quality and their safety is closely and continually monitored after approval.1

The Moderna vaccine has been approved for people 18 years and older and will be given in 2 doses 28 days apart.

Access to this vaccine is expected in September 2021 as the Australian Government has secured 25 million doses, with 10 million being delivered in 2021 and the remaining 15 million doses delivered in 2022.

Further information regarding the Covid-19 vaccinations, how they work, their safety and the contraindications and precautionary advice for Pfizer and Astra Zeneca vaccines can be found here - Australian Nursing & Midwifery Federation.

References
1.    Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised 11 June 2021) | International Coalition of Medicines Regulatory Authorities (ICMRA)
2.    TGA provisionally approves Moderna’s COVID-19 vaccine | Therapeutic Goods Administration (TGA)